BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 15231763)

  • 1. Trichosporon asahii infection treated with caspofungin combined with liposomal amphotericin B.
    Bassetti M; Bisio F; Di Biagio A; Pierri I; Balocco M; Soro O; Cruciani M; Bassetti D
    J Antimicrob Chemother; 2004 Aug; 54(2):575-7. PubMed ID: 15231763
    [No Abstract]   [Full Text] [Related]  

  • 2. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
    Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
    N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trichosporon asahii. Blood-stream infection in a non-cancer patient receiving combination antifungal therapy.
    O'Gorman C; McMullan R; Webb CH; Bedi A
    Ulster Med J; 2006 Sep; 75(3):226-7. PubMed ID: 16964817
    [No Abstract]   [Full Text] [Related]  

  • 4. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Schneemann M; Imhof A
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675094
    [No Abstract]   [Full Text] [Related]  

  • 5. Antifungal therapy in patients with fever and neutropenia--more rational and less empirical?
    Klastersky J
    N Engl J Med; 2004 Sep; 351(14):1445-7. PubMed ID: 15459307
    [No Abstract]   [Full Text] [Related]  

  • 6. Breakthrough Trichosporon asahii fungemia in neutropenic patient with acute leukemia while receiving caspofungin.
    Bayramoglu G; Sonmez M; Tosun I; Aydin K; Aydin F
    Infection; 2008 Feb; 36(1):68-70. PubMed ID: 17882360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Danaher PJ
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675092
    [No Abstract]   [Full Text] [Related]  

  • 8. An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy.
    Ellis M; Frampton C; Joseph J; Alizadeh H; Kristensen J; Hauggaard A; Shammas F
    J Med Microbiol; 2006 Oct; 55(Pt 10):1357-1365. PubMed ID: 17005784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caspofungin and amphotericin B for disseminated Fusarium verticillioides in leukemia.
    Makowsky MJ; Warkentin DI; Savoie ML
    Ann Pharmacother; 2005; 39(7-8):1365-6. PubMed ID: 15956243
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia.
    Asada N; Uryu H; Koseki M; Takeuchi M; Komatsu M; Matsue K
    Clin Infect Dis; 2006 Aug; 43(4):e39-41. PubMed ID: 16838224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caspofungin for invasive fungal infections: combination treatment with liposomal amphotericin B in children undergoing hemopoietic stem cell transplantation.
    Pancham S; Hemmaway C; New H; Albert E; Dokal I; Roberts IA; McCloy M
    Pediatr Transplant; 2005 Apr; 9(2):254-7. PubMed ID: 15787803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Tattevin P; Bareau B; Camus C
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675091
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B.
    Vazquez L; Mateos JJ; Sanz-Rodriguez C; Perez E; Caballero D; San Miguel JF
    Haematologica; 2005 Dec; 90(12 Suppl):ECR39. PubMed ID: 16464754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with caspofungin and amphotericin B lipid complex.
    Lum LR; Turco TF; Leone J
    Am J Health Syst Pharm; 2002 Jan; 59(1):80-1. PubMed ID: 11813474
    [No Abstract]   [Full Text] [Related]  

  • 15. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Jones BL; McLintock LA
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675090
    [No Abstract]   [Full Text] [Related]  

  • 16. Caspofungin versus liposomal amphotericin B for empirical therapy.
    Marty FM; Lowry CM
    N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675093
    [No Abstract]   [Full Text] [Related]  

  • 17. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK.
    Bruynesteyn K; Gant V; McKenzie C; Pagliuca T; Poynton C; Kumar RN; Jansen JP
    Eur J Haematol; 2007 Jun; 78(6):532-9. PubMed ID: 17419744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Successful treatment with caspofungin of an invasive candidosis resistant to liposomal amphotericin B in a neutropenic patient].
    Rome A; André N; Michel A; Coze C; Gentet JC; Bernard JL
    Arch Pediatr; 2006 Dec; 13(12):1556-7. PubMed ID: 17049216
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia.
    Fournier S; Pavageau W; Feuillhade M; Deplus S; Zagdanski AM; Verola O; Dombret H; Molina JM
    Eur J Clin Microbiol Infect Dis; 2002 Dec; 21(12):892-6. PubMed ID: 12525928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate.
    Goodman D; Pamer E; Jakubowski A; Morris C; Sepkowitz K
    Clin Infect Dis; 2002 Aug; 35(3):E35-6. PubMed ID: 12115115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.